News

2025

Areteia Therapeutics Announces Appointments of Donald J. Hayden, Jr. and Ian F. Smith to Its Board of Directors

Areteia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025

2024

Areteia Therapeutics Announces Appointment of Daniel Becker, M.D., Ph.D. To Board of Directors

Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma

Areteia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024

2023

Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma

Areteia Therapeutics Announces Appointment of Elyse Stock, M.D. To Board of Directors

Areteia Therapeutics Announces Start of Phase III Clinical Trials of Oral Dexpramipexole in Eosinophilic Asthma

Areteia Therapeutics Granted ILAP Designation from UK MHRA for Oral Dexpramipexole for Eosinophilic Asthma

2022

Areteia Therapeutics announces the appointment of Christopher Courts, CPA as Chief Financial Officer

Areteia Therapeutics announces the appointments of Dr. Eric Bradford as Chief Medical Officer, and Robin Walker as Chief Legal Officer and Corporate Secretary

Areteia Therapeutics named as one of the Most Promising Biotech Startups of 2022

Ian Read named Chairman of the Board of Areteia Therapeutics

Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding

Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 demonstrating that oral dexpramipexole improves airflow obstruction as measured by forced expiry volume (FEV1), largely through its effect on forced vital capacity (FVC)

2021

Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function

Knopp Biosciences Reports Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021

Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma

Dexpramipexole Targets Eosinophilic Inflammation

2020

Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma

Knopp Biosciences to Present at Oppenheimer’s Private Life Sciences Company Call Series Aug. 18

2019

Knopp Biosciences to Present Clinical Data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil Society

Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome

Knopp Biosciences Expands Research Collaboration with Cincinnati Children’s to Characterize Effect of Dexpramipexole in Inflammatory Diseases

2018

NIAID Now: Repurposed Drug Shows Promise for Treating Rare Eosinophilic Diseases

2017

Knopp Biosciences and APFED Announce Partnership to Advance Awareness of Hypereosinophilic Syndromes

We use only necessary cookies to ensure our website can work correctly and to enhance your experience. For more information about the cookies we use, please see our Cookie Policy.